RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today ...
47 分钟
Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈